Accelerators co-host Dr. Matt Spraker hosts Radiation Oncologists Drs. Krish Jethwa, Neil Newman, and Jeff Ryckman for part 2 of our discussion on radiotherapy for liver tumors. We kick off with Neil reviewing his Twitter thread comparing TACE and SBRT for liver tumors. We discuss the data supporting SBRT as superior therapy, especially in patients who have recurrence after TACE. We further share some talking points for your tumor board. Then discuss one of our faves, a randomized trial of sorafenib with or without SBRT (NRG/RTOG 1112). This leads to more discussion about how to approach large/unresectable liver tumors in your tumor board and possible future studies for these patients. Here are some things we discussed in the episode:Barcelona Liver StagingSapir et al., Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular CarcinomaComito et al., SBRT versus TACE/TAE for recurrence after TACEAkarapatima et al., TACE versus BSC for HCCXiang et al., TACE versus BSC for HCCLlovet et al., TACE/TAE versus BSC for HCC TRENDY trial., TACE versus SBRT for HCCBush et al., proton radiotherapy versus TACE for HCCVerbus et al., SBRT versus TACE as bridging therapy in HCC Hong et al., phase II trial of proton radiotherapy for unresectable cholangiocarcinomaRTOG 1112 survival curvesPodcast art generously donated by Dr. Danielle Cunningham. Intro and Outro music by Emmy-award winning artist Lucas Cantor Santiago.The Accelerators Podcast is a Photon Media production.